{
    "body": "What molecule is targeted by Avelumab?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27172898", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27350882", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26921031", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26014098", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27815822", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27544053", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27490642", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27592805", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26880697", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26477470", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27716622", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27196116"
    ], 
    "ideal_answer": [
        "Avelumab is a monoclonal antibody that binds programmed death-ligand 1 (PD-L1)."
    ], 
    "exact_answer": [
        "programmed death-ligand 1", 
        "PD-L1"
    ], 
    "type": "factoid", 
    "id": "5884c72fe56acf517600000f", 
    "snippets": [
        {
            "offsetInBeginSection": 240, 
            "offsetInEndSection": 409, 
            "text": "Several drugs targeting PD-1 (pembrolizumab and nivolumab) or PD-L1 (atezolizumab, durvalumab, and avelumab) have been approved or are in the late stages of development.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27196116", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 644, 
            "offsetInEndSection": 923, 
            "text": "We then focus on the recent breakthrough work concerning the structural basis of the PD-1/PD-Ls interaction and how therapeutic antibodies, pembrolizumab targeting PD-1 and avelumab targeting PD-L1, compete with the binding of PD-1/PD-L1 to interrupt the PD-1/PD-L1 interaction. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27815822", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 193, 
            "text": "Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti-programed death-ligand 1 (Avelumab).", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27490642", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 683, 
            "offsetInEndSection": 829, 
            "text": "In addition, we assessed the safety and biological activity of a human anti-PD-L1 antibody (Avelumab) in chronically SIV-infected rhesus macaques.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27490642", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 439, 
            "offsetInEndSection": 608, 
            "text": "We assessed treatment with avelumab, an anti-PD-L1 monoclonal antibody, in patients with stage IV Merkel cell carcinoma that had progressed after cytotoxic chemotherapy.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27592805", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 99, 
            "text": "Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27716622", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 220, 
            "offsetInEndSection": 448, 
            "text": "Here, we describe the efficacy of NIR-PIT, using fully human IgG1 anti-PD-L1 monoclonal antibody (mAb), avelumab, conjugated to the photo-absorber, IR700DX, in a PD-L1 expressing H441 cell line, papillary adenocarcinoma of lung.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27716622", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1075, 
            "offsetInEndSection": 1313, 
            "text": "In conclusion, the anti-PD-L1 antibody, avelumab, is suitable as an APC for NIR-PIT. Furthermore, NIR-PIT with avelumab-IR700 is a promising candidate of the treatment of PD-L1-expressing tumors that could be readily translated to humans.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27716622", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 125, 
            "text": "Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26014098", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 612, 
            "offsetInEndSection": 683, 
            "text": "MSB0010718C (designated avelumab) is a fully human IgG1 anti-PD-L1 mAb.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26014098", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1409, 
            "offsetInEndSection": 1576, 
            "text": "These studies thus provide an additional mode of action for an anti-PD-L1 mAb and support the rationale for further studies to enhance avelumab-mediated ADCC activity.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26014098", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 644, 
            "offsetInEndSection": 922, 
            "text": "We then focus on the recent breakthrough work concerning the structural basis of the PD-1/PD-Ls interaction and how therapeutic antibodies, pembrolizumab targeting PD-1 and avelumab targeting PD-L1, compete with the binding of PD-1/PD-L1 to interrupt the PD-1/PD-L1 interaction.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27815822", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 2142, 
            "offsetInEndSection": 2241, 
            "text": "In addition, mesothelioma tumor cells are susceptible to ADCC by the anti-PD-L1 antibody avelumab..", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27544053", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 125, 
            "text": "Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26921031", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 664, 
            "offsetInEndSection": 810, 
            "text": "In addition, we assessed the safety and biological activity of a human anti-PD-L1 antibody (Avelumab) in chronically SIV-infected rhesus macaques.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27490642", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 781, 
            "offsetInEndSection": 1006, 
            "text": "Different mechanisms to prevent immunologic escape have been characterized during the last years; in particular the PD-1/PD-L1 inhibitors pembrolizumab, avelumab, durvalumab and atezolizumab have shown early sign of efficacy.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26880697", 
            "endSection": "abstract"
        }
    ]
}